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In our collective enthusiasm to diagnose and treat disease, a growing body of evidence indicates that we may often be doing too much of a good thing.
1-5 "Overdiagnosis" is now widely recognised to occur when people are labelled with or treated for a disease that would never cause them harm-often as a result of undergoing screening-and it can lead to the overuse of further tests and treatments.
2 6 One example is thyroid cancer, with estimates that over 500 000 people may have received overdiagnoses across 12 countries in the past two decades, leading to unnecessary surgery and lifelong medication for many. 7 Overdiagnosis is a challenge to the sustainability of human health and health systems. Its causes-including the best of intentions-are as complex and multifaceted as the potential solutions. [8] [9] [10] [11] [12] [13] As part of the preparation for a possible national action plan in Australia, we searched the literature for causes of and responses to overdiagnosis. Here we provide the first comprehensive analysis of the possible drivers of overdiagnosis and related overuse, mapped to potential solutions.
Searching the literature
Our approach to the initial and updated PubMed searches of the literature is outlined in the data supplement (see bmj.com) and yielded a total of 36 articles, to which we added a further five ( fig 1⇓) . We included articles that explicitly discussed possible drivers and potential responses or solutions to the problem of overdiagnosis. We included original research as well as opinion, commentary, and analysis articles. Reflecting the relatively recent and growing interest in overdiagnosis, the vast majority were published since 2013, with generally increasing numbers each year (rising from three before 2013 to nine in 2016 and four in 2017 up until July).
Given the limitations of the literature to date, we couldn't assess the quality of evidence behind each claim in each article, so this is not a systematic review. The vast majority of included articles are analyses or commentaries, with a small number of important exceptions, including a systematic review. Although discussion of drivers and solutions in many of the included analysis pieces were informed directly by empirical evidence, including systematic reviews the original studies are not included here, as they did not explicitly discuss drivers or solutions in ways captured by our search strategy. The body of empirical evidence highlighting the problem of overdiagnosis is growing, but a systematic review is beyond the scope of this article. Similarly, although analysing the complex inter-relation between overdiagnosis and the overuse it drives 14 is vitally important, it is outside the reach of this article.
The map arising from our analysis is broad but not definitive-potential causes or solutions might not yet have been identified in the literature, and breadth might come at the cost of depth. In addition, our search was based in medicine, and a wider analysis might identify important sociological investigations of medicalisation 15 resulting in different conceptions of the problem, drivers, and solutions. Importantly no strict or established criteria for what defines a driver or a solution exist, so our decisions about inclusion and mapping are open to discussion. Moreover, individual items could in some cases map to more than one domain. We have made no attempt to integrate this map with the extensive science of behaviour change 16 or to specify potential actors to work on solutions, but hope that others will pursue this work.
Popular deep seated beliefs that in healthcare "more is better" and "new is better" are often cited as drivers of unnecessary testing and overdiagnosis. Related to this is a strong collective faith in the benefits of screening the healthy and making an early diagnosis, arising in part from our fears of a serious disease being missed or a diagnosis made too late.
3-29 As Welch, Schwartz, and Woloshin argue in their 2011 book Overdiagnosed, which draws on a wealth of empirical evidence, "early diagnosis is a double edged sword," with the potential to help but also hidden danger: "the detection of abnormalities that are not destined to ever bother us."
2 Fears of uncertainty, ageing, death, and disease also collectively contribute to this culture of too much medicine.
8-47
Health system drivers Expanding disease definitions, which identify more previously healthy people as "sick," are commonly cited as a driver of overdiagnosis.
3-47 Health professionals and hospitals frequently have financial incentives to perform more investigations or treatments for their patients, favouring increased and sometimes unnecessary care. Moreover, a system based on fee for service may lead to time restraints during consultations with inadequate time available for shared decision making or the complex explanation of the counterintuitive problem of overdiagnosis.
4-32
As Malvinder Parmar said, "the current fee-for-service system does not compensate for a comprehensive explanation to the patient why a test is not required."
9 Current quality measures in health systems may lack emphasis on preventing overdiagnosis or overuse and instead may indirectly promote these problems.
3-21
Industry and technology drivers
The most important driver in this domain is the use and promotion (to clinicians and the public) of increasingly sensitive tests, leading to detection-often incidentally-of minor "abnormalities," which may be of uncertain clinical significance and can cause overdiagnosis.
3-47 Industry promotion can also include the funding of patient and advocacy groups. As Eric Coon and colleagues point out in their well reasoned and evidence based exploration of potential drivers of overdiagnosis among children, "Advertisements capitalize on our fear of undiagnosed disease and urge us to see our doctor for testing . . . Once considered unbiased, third party advocacy groups are often used to deliver the same message." 17 Commercial imperatives and conflicts of interest, including financial or reputational conflicts of interests of those involved in guideline panels that expand disease definition, are also cited as a concern.
3-47
Professional drivers
Many authors argue that health professionals are driven to practise defensive medicine owing to their fear of litigation arising from a purported omission.
3-41 Closely related is the doctor's fear of missing a diagnosis, also commonly cited as a potential driver of overdiagnosis.
3-29 Health professionals' unease with dealing with an uncertain diagnosis may lead them towards overtesting and overdiagnosis. This lack of professional confidence and knowledge of harms, as well as the tendency to routinely diagnose or "do something" may arise from flaws in medical training, 9-23 with underemphasis on patient preferences and overemphasis on diagnosis.
20-47
Patient and public drivers
While important, the results of our analysis indicate that this domain has received less attention in the literature, although it clearly overlaps with the culture domain. A number of authors point to a perception that many people have a lack of knowledge about the limits to, and harms of, medicine and suggest that patients tend to over-rely on tests, including as a means of reassurance. Others identify patient expectations that clinicians will "do something" as a potential driver.
9-21
What are the potential solutions?
Many of the potential solutions commonly identified in the literature map closely to explicit drivers, with some important exceptions (table 1⇓) . For some drivers, such as the increasing complexity and fragmentation of care, specific relevant solutions were not identified. Other drivers showed considerable overlap, both within and across domains. The health system domain, for example, overlaps with the industry and technology domain, where enhanced government regulation of commercial promotion or health technology evaluation clearly falls primarily to policy makers. We made every attempt to link drivers to potential solutions.
Culture solutions
Public awareness and education campaigns are needed to challenge beliefs that in healthcare "more is better" 9-26 and to promote a more healthy scepticism about the benefits and potential harms of early diagnosis.
2-22 Arguably, initiatives like The BMJ's Too Much Medicine campaign, 48 Choosing Wisely, 49 JAMA Internal Medicine's "Less is more," 50 and Health News Review 51 are moving in this direction. Given the powerful role that media can play in shaping public beliefs, strategies to improve media reporting on overdiagnosis are needed.
2-28
Health system solutions
Reforming incentives for professionals and healthcare organisations to reward the quality rather than quantity of care is commonly cited as a key way to tackle the problem of too much medicine.
3-30 Some authors also cite the need for new evidence informed frameworks to be used when disease definitions are changed, 52 with calls for changes to disease terminology and new expert panels that are more widely representative and have reduced or minimal conflicts of interests.
3-37 An influential group convened by the US National Cancer Institute is among those advocating changes to disease terminology for indolent lesions. 26 Quality indicators and guidelines are also targeted for reform, to tackle any incentives More targeted screening programmes that might, for example, limit some screening to well defined high risk populations 9-39 and mandated strategies to inform patients of the benefits and harms of screening 3-36 are among potential solutions for minimising the risks of overdiagnosis associated with screening. The 2016 systematic review of studies aimed at reducing low value care and underuse across different parts of the health system found that interventions using multiple strategies and targeting the roles of both clinicians and consumers had the greatest potential.
10
Industry and technology solutions
More rigorous evaluation of the effects of both new and existing diagnostic technology on health outcomes is commonly recommended 3-39 as a key solution to the problem of increasingly sensitive tests that detect "abnormalities" of uncertain clinical significance. Drawing from the field of ecological economics to frame overdiagnosis as overconsumption , Hensher and colleagues call for "a more rigorous application of the precautionary principle" in technology assessment to avoid giving "potentially harmful overuse the benefit of the doubt." 12 Other potential solutions include stronger regulation of the advertising of new tests and treatments to the public and health professionals 30 and paying greater attention to managing and reducing conflicts of interest with industry. 47 
Professional solutions
The need to tackle the medicolegal concerns regarding missing or delaying a diagnosis was one of the key solutions discussed in the literature.
3-47 Another recommended solution is updating current medical curriculums and continuing medical education to include overdiagnosis and overuse, for both students and practitioners.
3-47 As future practitioners, students must be taught to "look always for the possibility of harm alongside that of benefit." 25 This is vital because, according to Eric Coon and colleagues, "if physicians are not aware of the potential harms of overdiagnosis, patients and families cannot be expected to appreciate them either."
17
Patients and the public solutions
Widespread awareness campaigns to inform and educate patients and the public on harms as well as benefits of screening and treatment options are commonly cited as essential to tackling overdiagnosis, 3-47 echoing and overlapping with solutions we have classified in the cultural domain. Another frequently recommended solution was promoting shared decision making as a response to several key drivers in this domain. In addition, several authors proposed the need for prioritising treatment options such as watchful waiting or active surveillance, where appropriate.
3-35
Where to from here?
We have attempted to retrieve, analyse, and summarise the existing literature on drivers and responses to overdiagnosis and related overuse. Many authors have identified a wide range of potential solutions across five inter-related domains of culture, the health system, industry and technology, professionals, and patients, with the ultimate shared aims to prevent harm, reduce waste, and redirect resources to treating and preventing unmet need in healthcare. The results of this analysis emphasise the need for more evidence about the problem, increased evaluation of potential solutions, and enhanced education across all sectors, to help wind back the harms of too much medicine effectively, safely, and fairly.
As part of multiple level strategies, in our view the most urgent need is to generate accessible evidence based information and educational materials about overdiagnosis for the public, professionals, and decision makers-both general information and condition specific. Tackling the gamut of financial incentives that drive unnecessary diagnoses and strengthening regulatory processes to enhance evaluation of new and existing diagnostic technology are two more solutions, as difficult as they are desirable. Reforming inappropriately widened disease definitions is arguably the most challenging but most important solution.
We strongly encourage critical responses to this analysis, offering alternative interpretations or missed drivers or solutions. Indeed optimising societies' responses to medical excess will require broader thinking and analysis outside medicine-from such places as economics and sociology.
As the evidence base around this problem continues to grow, so do attempts to translate that evidence into action. In Norway, a position paper from the College of General Practice calls for action 53 ; in Australia, major influential professional and consumer organisations are launching a national plan; and in Canada, the Quebec Medical Association is already implementing a province-wide strategy. Building on existing initiatives, we hope this analysis will help offer a suite of possible solutions to those seeking to reduce iatrogenic harm and enhance health system sustainability.
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Reform guidelines on tests and treatments:
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Potential solutions Possible drivers
Better regulate advertising 30 Industry promotion of tests and treatments to professionals and public:
Advertising (including direct to consumer marketing), promotion, influence using the media to generate demand for diagnosis Industry funding of patient and advocacy groups Industry wants to develop better diagnostic technology-technological arms race [19] [20] [21] [22] [23] [24] Better evaluation of diagnostic technology:
Better evaluation of new and existing diagnostic technology Evaluate effects of test-treatment strategies on outcomes, not just test performance alone, more caution in treating incidentalomas Better identify harmful v benign abnormalities 3 27 Increasing specificity of tests at the cost of slightly decreased sensitivity 39 Include patient voice in development, assessment, implementation, and use of technology 24 Strengthen health technology assessments and cost effectiveness analyses 12 Diagnostic tests with increased sensitivity:
New technology captures ever smaller "abnormalities"or iincidental findings Changes nature and prevalence of disease 20 24 Feedback loop: diagnosing milder cases, high prevalence, better outcomes, more tests and treatments-illusion of progress Declare, reduce, exclude conflicts of interest 19 Medicine as a business and conflicts of interest Commercial and corporate clinics-self referral, vertical integration 3 8
Commercial and other conflicts of interest Professional conflicts of interest, specialist societies protecting or expanding turf [3] [4] [5] [6] [7] [8] [9] Toxic combination of vested interests and good intentions 25 Supply-sensitive care 17 Better evaluation of changes to (expansion of) disease definitions 34 Industry interest in expanding markets, including financial ties to those setting diagnostic thresholds Critical thinking and comfort with uncertainty (eg, with a period of active surveillance, watchful waiting) Fear of missing disease or decision regret Educational curricula and information materials on overdiagnosis and overuse for students and professionals Flaws in training:
Hard to do nothing rather than something [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Overemphasis on diagnosis 20 Problem based learning approach leads to shotgun approach to diagnosis, rewards unusual or rare diagnoses, and contributes to overtesting and overdiagnosis, with an emphasis on avoiding omission errors Poor knowledge of patient preference and shared decision making 23 Improper weighting of absolute v relative risk Lack of professional self confidence or knowledge of harms Interventions to reduce overuse and overdiagnosis:
Multicomponent interventions tackling patient and provider roles (eg, clinician education with decision support or feedback) to reduce overuse and low value care 10 Using minimally invasive techniques to eventually replace surgery for low risk tumours (eg, low staged lung tumours) 39 Clinical decision support and performance feedback 10 13 Compare practices with peers (eg, prescribing, referrals, tests) More time with patient to order less tests 30 46 Tools to promote discussion with patients on why test might not be needed 13 Don't use diagnostic labels unless needed 33 Consider stepped or slower diagnosis 17 33 Overusing or over-reliance on tests Lack of knowledge or confidence about limits and harms of medicine 8 23 Research and promote doing nothing, watchful waiting, or active surveillance as legitimate options, where appropriate Expectation that clinicians will "do something" 
